Stay updated on Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial page.

Latest updates to the Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedAdded recruitment status and new user guidance sections, and updated the Intervention/Treatment heading and revision version, while removing the older formatting of the heading and the older revision label.SummaryDifference0.4%

- Check18 days agoChange DetectedThe revision tag on the page was updated from v3.5.4 to v3.5.5, indicating a new version of the page. This appears to be a small, behind-the-scenes update with no changes to visible study information.SummaryDifference0.1%

- Check40 days agoChange DetectedThe page shows Revision: v3.5.4, replacing the previous v3.5.3, indicating a software/version update to the page rendering. This update is an internal maintenance change rather than a modification to the study text or data.SummaryDifference0.1%

- Check54 days agoChange DetectedA new revision tag v3.5.3 is added, replacing the previous v3.5.2. This reflects a minor update to the page's revision/version information.SummaryDifference0.1%

- Check68 days agoChange DetectedFooter now shows Revision: v3.5.2, replacing Revision: v3.5.0. This is a technical update with no impact on study information or user actions.SummaryDifference0.1%

- Check83 days agoChange DetectedAdded 'Squamous cell carcinoma of the head and neck' as a listed condition in the study details.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial page.